UK Markets open in 7 hrs 54 mins

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
6.50-0.10 (-1.52%)
At close: 04:35PM GMT

Shield Therapeutics plc

Northern Design Centre
Baltic Business Quarter
Gateshead NE8 3DF
United Kingdom
44 1915 118 500

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees15

Key executives

NameTitlePayExercisedYear born
Mr. Gregory P. MadisonCEO & Exec. Director432.57kN/A1968
Dr. Christian Schweiger M.D., Ph.D.Co-Founder & Non Exec. Director50kN/A1967
Mr. Hans-Peter RudolfChief Financial OfficerN/AN/AN/A
Ms. Lucy Huntington-BaileyGen. Counsel & Company Sec.N/AN/AN/A
Ms. Suzanne WoodGroup HR DirectorN/AN/AN/A
Ms. Carol AkinolaHead of Pharmacovigilance & Medical InformationN/AN/AN/A
Dr. José A. Menoyo M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Corporate governance

Shield Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.